このコーナーでは、L-FABP関連の論文を、慢性腎臓病（CKD）、急性腎障害（AKI）、Toxicology、Pharmacologyに分類し、紹介いたします。
文献・資料をご希望の際は、資料請求ページの備考欄に見出し番号（文献リストの赤色の数字）を入力の上、ご連絡ください。

資料請求はこちら ▶

文献カテゴリー

慢性腎臓病（CKD）　急性腎障害（AKI）　薬剤性腎障害（Toxicology）
薬理学（Pharmacology）　運動（Exercise）　新型コロナウイルス感染症（COVID-19）　日本語総説　ガイドラインなど

慢性腎臓病（CKD） 【新着】

• 224 Comparison of Urinary Liver Fatty Acid Binding Protein Level and Pathologic Biopsy Findings 1 Year After Kidney Transplantation. Transplant Proc. 2024
  doi: 10.1016/j.transproceed.2023.12.016. PubMed
• 218 Urinary Liver-Type Fatty Acid Binding Protein, a Biomarker for Disease Progression, Dialysis and Overall Mortality in Chronic Kidney Disease. J Pers Med. 2023
  doi: 10.3390/jpm13101481. PubMed
• 214 Cross-Sectional and Longitudinal Associations between Skin Autofluorescence and Tubular Injury Defined by Urinary Excretion of Liver-Type Fatty Acid-Binding Protein in People with Type 2 Diabetes. Biomedicines. 2023
  doi: 10.3390/biomedicines11113020. PubMed
• 211 Elevated urinary angiotensinogen excretion links central and renal hemodynamic alterations. Sci Rep. 2023
  doi: 10.1038/s41598-023-38507-w PubMed
• 210 Association of urinary liver-type fatty acid-binding protein with outcomes after adrenalectomy for unilateral primary aldosteronism. Clin Chim Acta.2023
  doi: 10.1016/j.cca.2023.117465. PubMed

慢性腎臓病（CKD）関連文献の一覧へ ▶

急性腎障害（AKI） 【新着】

• 223 Unravelling the role of urinary liver-type fatty acid binding protein in histone-induced AKI. Nephrology (Carlton). 2024
  doi: 10.1111/nep.14271. PubMed
• 222 How to Construct an Optimal Risk Model for Contrast-induced Nephropathy. Intern Med. 2024
  doi: 10.2169/internalmedicine.3209-23. PubMed
• 221 The Experience of Using Urinary Liver-Type Fatty Acid-Binding Protein for Follow-Up of Toluene Poisoning: A Case Report. Cureus. 2023
  doi: 10.7759/cureus.50438. PubMed
• 220 Evaluation of amniotic fluid neutrophil gelatinase-associated lipocalin and L-type fatty acid-binding protein levels during pregnancy. Eur J Obstet Gynecol Reprod Biol X. 2023
  doi: 10.1016/j.eurox.2023.100269. PubMed
• 219 Predictive Performance of Neutrophil Gelatinase Associated Lipocalin, Liver Type Fatty Acid Binding Protein, and Cystatin C for Acute Kidney Injury and Mortality in Severely Ill Patients. Ann Lab Med. 2024
  doi: 10.3343/alm.2023.0083. PubMed

急性腎障害（AKI）関連文献の一覧へ ▶

薬剤性腎障害（Toxicology） 【新着】

• 201 Urinary liver-type fatty acid-binding protein in two dogs with acquired Fanconi syndrome: A case report. Open Vet J.2022
  doi: 10.5455/OVJ.2022.v12.i6.12 PubMed
• 188 Urinary L-type fatty acid-binding protein is a predictor of cisplatin-induced acute kidney injury. BMC Nephrol.2022
  doi: 10.1186/s12882-022-02760-4. PubMed
• 184 Clinical Utility of a Biomarker to Detect Contrast-Induced AcuteKidney Injury during Percutaneous Cardiovascular Procedures. Cardiorenal Med.2022
  doi: 10.1159/000520820. PubMed
• 167 Changing trends in lipid profile and biomarkers of renalfunction and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofoviralafenamide: a prospective observational study. AIDS Res Ther.2021
  doi:10.1186/s12981-021-00354-y. PubMed
• 153 Early changes in tubular dysfunction markers and phosphorusmetabolism regulators as a result of switching from entecavir to tenofovir alafenamide fumarate nucleosideanalog therapy for chronic hepatitis B patients. Hepatol Res.2020
  doi:10.1111/hepr.13451. PubMed

薬剤性腎障害（Toxicology）関連文献の一覧へ ▶

薬理学（Pharmacology） 【新着】

• 217 Urinary liver-type fatty acid binding protein is a biomarker reflecting renal damage and the ameliorative effect of drugs at an early stage of histone-induced acute kidney injury. Nephrology (Carlton). 2023
  doi: 10.1111/nep.14254. PubMed
• 206 Markers of Kidney Tubular Function Deteriorate While Those of Kidney Tubule Health Improve in Primary Aldosteronism After Targeted Treatments. J Am Heart Assoc.2023
  doi: 10.1161/JAHA.122.028146. PubMed
• 205 Association of urinary liver-type fatty acid-binding protein with renal functions and antihyperglycemic drug use in type 2 diabetic nephropathy patients. Int Urol Nephrol.2023
  doi: 10.1007/s11255-023-03532-1. PubMed
• 182 Tubular Injury Causing Protracted GlycosuriaFollowing Withdrawal of a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor: A Possible Role in theDevelopment of Protracted Hypoglycemia and Ketoacidosis. Tohoku J ExpMed.2021
  doi: 10.1620/tjem.255.291. PubMed

薬理学（Pharmacology）関連文献の一覧へ ▶

運動（Exercise） 【新着】

• 197 The moderate-intensity continuous exercise maintains renal blood flow and does not impair the renal function . Physiol Rep. 2022
  doi: 10.14814/phy2.15420. PubMed
• 194 Xanthine Oxidoreductase Activity in MarathonRunners: Potential Implications for Marathon-Induced Acute Kidney Injury. JAppl Physiol. 2022
  doi: 10.1152/japplphysiol.00669.2021. PubMed
• 181 Wearing a face mask during controlled-intensity exercise is nota risk factor for exertional heatstroke: A pilot study. Acute MedSurg.2021
  doi: 10.1002/ams2.712. PubMed
• 178 Exercise Ameliorates Diabetic Kidney Disease in Type 2 DiabeticFatty Rats. Antioxidants (Basel).2021
  doi: 10.3390/antiox10111754. PubMed
• 148 Effects of exercise on residual renal function in patientsundergoing peritoneal dialysis: a post-hoc analysis of a randomized controlled trial. Ther Apher Dial.2020
  PubMed

運動（Exercise）関連文献の一覧へ ▶

新型コロナウイルス感染症（COVID-19） 【新着】

• 217 Urinary liver-type fatty acid binding protein is a biomarker reflecting renal damage and the ameliorative effect of drugs at an early stage of histone-induced acute kidney injury. Nephrology (Carlton). 2023
  doi: 10.1111/nep.14254. PubMed
• J49 当院での新型コロナウイルス感染症（COVID-19）入院患者から検討した重症化予測因子 内科2023
• 209 Urinary liver-type fatty acid binding protein is increased in the early stages of the disease with a risk of acute kidney injury induced by histone. Nephrology (Carlton).2023
  DOI: 10.1111/nep.14162 PubMed
• 208 Urinary L-Type Fatty Acid-Binding Protein Predicts Oxygen Demand of COVID-19 in Initially Mild Cases. Care Explor. 2023
  doi: 10.1097/CCE.0000000000000873. PubMed
• 204 Evaluation of Urine L-FABP Point of Care Kit in the Philippines as Predictive Marker of Clinical Severity of COVID-19 (EPOCH COVID study). Philipp J Intern Med. 2022 PJIM

新型コロナウイルス感染症（COVID-19）一覧へ ▶

日本語総説 【新着】

• J49 当院での新型コロナウイルス感染症（COVID-19）入院患者から検討した重症化予測因子 内科2023
• J48 COVID－19と高血圧症・腎疾患 The Lipid33(1) 2022
• J47 【CKD 患者における抗がん薬治療】がん薬物療法前のAKIリスク評価とAKIバイオマーカー 腎と透析93(3) 2022
• J46 慢性腎臓病の重症化予防に向けた運動の役割 体力科学誌2019
• J45 習慣的な運動による老化関連疾患の予防 医学のあゆみ2018

日本語総説の一覧へ ▶

ガイドラインなど

一覧へ ▶

文献・資料をご希望の際は、資料請求ページの備考欄に見出し番号（下記リストの最初の数字）を入力の上、ご連絡ください。

資料請求はこちら ▶

文献カテゴリー

慢性腎臓病（CKD）　急性腎障害（AKI）　薬剤性腎障害（Toxicology）
薬理学（Pharmacology）　運動（Exercise）　新型コロナウイルス感染症（COVID-19）　日本語総説　ガイドラインなど